Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 13;1(7):69.
doi: 10.1186/gm69.

Genomic Advances and Their Impact on Clinical Trial Design

Free PMC article

Genomic Advances and Their Impact on Clinical Trial Design

Sumithra J Mandrekar et al. Genome Med. .
Free PMC article


Medical treatment for patients has historically been based on two primary elements: the expected outcome for the patient, and the ability of treatment to improve the expected outcome. The advance in genomic technologies has the potential to change this paradigm and add substantial value to current medical practice by providing an integrated approach to guide patient-specific treatment selection using the genetic make-up of the disease and the genotype of the patient. Specifically, genomic signatures can aid in patient stratification (risk assessment), treatment response identification (surrogate markers), and/or in differential diagnosis (identifying who is likely to respond to which drug(s)). Several critical issues, including scientific rationale, clinical trial design, marker assessment methods, cost and feasibility have to be carefully considered in the validation of biomarkers through clinical research before they can be routinely integrated into clinical practice. Here, we highlight the impact of genomic advances on various aspects of clinical trial design.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles


    1. Conley BA, Taube SE. Prognostic and predictive markers in cancer. Dis Markers. 2004;20:35–43. - PMC - PubMed
    1. Taube SE, Jacobson JW, Lively TG. Cancer diagnostics: decision criteria for marker utilization in the clinic. Am J Pharmacogenomics. 2005;5:357–364. - PubMed
    1. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25:587–595. - PubMed
    1. Bonomi PD, Buckingham L, Coon J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007;13:s4606–s4612. - PubMed
    1. Slamon D. Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs. 2000;4(Sa):24–29. - PubMed

Publication types

LinkOut - more resources